GILEAD | Medical Information

Tybost® (cobicistat) Product Retirement

This document is in response to your request for information regarding Tybost® (cobicistat) and Gilead's decision to retire the product.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/tybost/tybost_pi.

Why is Gilead Retiring Tybost®?

Gilead has decided to discontinue the commercial sale of Tybost (cobicistat) 150 mg and 90 mg tablets in the US, effective February 2026. Product supply is expected to remain available through authorized distributors until that date. Gilead has notified the FDA of its decision to withdraw the product from the market.

Gilead's decision to withdraw Tybost single agent from the US is due to a sharp decline in use, as observed in the progressively lower volumes demanded worldwide because of the availability of multiple other clinical options for treating patients with HIV-1. The decision to discontinue supply is not related to product safety, efficacy, or quality.

Gilead believes that the withdrawal of Tybost will not create any unmet need for people with HIV, given the wide availability of several other authorized and guideline-recommended therapeutics.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Tybost US Prescribing Information available at: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/tybost/tybost_pi.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.